CN116763791A - 化合物以及它们的使用方法 - Google Patents

化合物以及它们的使用方法 Download PDF

Info

Publication number
CN116763791A
CN116763791A CN202310582446.9A CN202310582446A CN116763791A CN 116763791 A CN116763791 A CN 116763791A CN 202310582446 A CN202310582446 A CN 202310582446A CN 116763791 A CN116763791 A CN 116763791A
Authority
CN
China
Prior art keywords
alkyl
carbocyclyl
optionally substituted
heterocyclyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310582446.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·雷迪
G·马蒂内兹博特拉
A·M·格里芬
B·E·马龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Medicines Inc
Original Assignee
Praxis Precision Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines Inc filed Critical Praxis Precision Medicines Inc
Publication of CN116763791A publication Critical patent/CN116763791A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202310582446.9A 2016-11-28 2017-11-28 化合物以及它们的使用方法 Pending CN116763791A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662427044P 2016-11-28 2016-11-28
US62/427,044 2016-11-28
US201762458306P 2017-02-13 2017-02-13
US62/458,306 2017-02-13
US201762552073P 2017-08-30 2017-08-30
US62/552,073 2017-08-30
CN201780084790.8A CN110337295B (zh) 2016-11-28 2017-11-28 化合物以及它们的使用方法
PCT/US2017/063533 WO2018098499A1 (en) 2016-11-28 2017-11-28 Compounds and their methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780084790.8A Division CN110337295B (zh) 2016-11-28 2017-11-28 化合物以及它们的使用方法

Publications (1)

Publication Number Publication Date
CN116763791A true CN116763791A (zh) 2023-09-19

Family

ID=62195384

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310582446.9A Pending CN116763791A (zh) 2016-11-28 2017-11-28 化合物以及它们的使用方法
CN201780084790.8A Active CN110337295B (zh) 2016-11-28 2017-11-28 化合物以及它们的使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780084790.8A Active CN110337295B (zh) 2016-11-28 2017-11-28 化合物以及它们的使用方法

Country Status (14)

Country Link
US (3) US11629146B2 (https=)
EP (2) EP3548033B1 (https=)
JP (4) JP7105797B2 (https=)
CN (2) CN116763791A (https=)
AU (3) AU2017364901A1 (https=)
BR (1) BR112019010880A2 (https=)
CA (2) CA3281817A1 (https=)
DK (1) DK3548033T3 (https=)
ES (1) ES2992063T3 (https=)
FI (1) FI3548033T3 (https=)
HU (1) HUE068842T2 (https=)
PL (1) PL3548033T3 (https=)
PT (1) PT3548033T (https=)
WO (1) WO2018098499A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026082004A1 (zh) * 2024-10-14 2026-04-23 上海京新生物医药有限公司 稠合杂芳基衍生物及其制备方法与应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
MX2020012838A (es) 2018-05-30 2021-07-16 Praxis Prec Medicines Inc Moduladores de los canales ionicos.
BR112021003224A2 (pt) 2018-08-20 2021-07-20 Rogcon, Inc. oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a
EA202092908A1 (ru) * 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
WO2021039961A1 (ja) * 2019-08-30 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体
CN114980899A (zh) * 2019-11-26 2022-08-30 普拉西斯精密医药公司 离子通道调节剂
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
PE20221280A1 (es) * 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
JP2021195367A (ja) * 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
PE20242111A1 (es) 2021-09-13 2024-10-28 Boehringer Ingelheim Vetmedica Gmbh Derivados de etilsulfonil-piridina sustituidos con ciclopropil-(hetero)arilo
KR20250005348A (ko) * 2022-04-26 2025-01-09 프락시스 프리시젼 메디신즈, 인크. 신경 장애의 치료
CN120641418A (zh) * 2022-10-07 2025-09-12 腾维治疗公司 化合物、组合物和方法
CN119613413B (zh) * 2024-12-26 2026-02-06 上海皓元医药股份有限公司 一种非唑奈坦的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5340798A (en) * 1976-09-22 1978-04-13 American Cyanamid Co Production of substituted phenyll1*2*44triazolo *4*33b* pyrodazines * acid addition salt and treating composition
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
CN1816346A (zh) * 2003-05-29 2006-08-09 新河药品股份有限公司 耐滥用的苯异丙胺化合物
CN102725290A (zh) * 2009-07-27 2012-10-10 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
TW201609741A (zh) * 2014-06-04 2016-03-16 盧郡控股（開曼）有限公司 作為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之二氟乙基吡啶衍生物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4230705A (en) * 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9507348D0 (en) 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
WO2002006286A2 (en) 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
AU2005212096B2 (en) * 2004-02-18 2010-12-16 Msd K.K. Nitrogenous fused heteroaromatic ring derivative
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
CA2713521A1 (en) 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
MX342128B (es) 2008-12-24 2016-09-14 Bial - Portela & C A S A Compuestos farmaceuticos.
JP5340798B2 (ja) 2009-05-07 2013-11-13 タイガースポリマー株式会社 地中埋設管の製造方法
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
FR2953520B1 (fr) 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2012151136A1 (en) 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (https=) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2013045519A1 (en) 2011-09-27 2013-04-04 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
JP2016511744A (ja) 2012-12-21 2016-04-21 エピザイム，インコーポレイティド Ｐｒｍｔ５を阻害する方法
WO2014179492A1 (en) 2013-05-01 2014-11-06 Gilead Sciences, Inc. Combination therapy for the treatment of arrhythmias or heart failure
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
DK3035926T3 (da) 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
NZ720651A (en) 2013-12-19 2017-12-22 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
ES2912073T3 (es) 2014-06-20 2022-05-24 Mitsubishi Chem Corp Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
AU2015279377B2 (en) 2014-06-26 2019-09-12 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin-2-one derivatives
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098500A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
MX2020012838A (es) 2018-05-30 2021-07-16 Praxis Prec Medicines Inc Moduladores de los canales ionicos.
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
CN114980899A (zh) 2019-11-26 2022-08-30 普拉西斯精密医药公司 离子通道调节剂
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5340798A (en) * 1976-09-22 1978-04-13 American Cyanamid Co Production of substituted phenyll1*2*44triazolo *4*33b* pyrodazines * acid addition salt and treating composition
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
CN1816346A (zh) * 2003-05-29 2006-08-09 新河药品股份有限公司 耐滥用的苯异丙胺化合物
CN102725290A (zh) * 2009-07-27 2012-10-10 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
TW201609741A (zh) * 2014-06-04 2016-03-16 盧郡控股（開曼）有限公司 作為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之二氟乙基吡啶衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL CATALOG: "CAS Registry Number：1002310-67-9", 《STN REGISTRY》, 10 February 2008 (2008-02-10), pages 1 *
GRAY M. COPPOLA等: "Pyrimidones. 2. Synthesis and Reactions of 2-Chloropyrimidines", 《J. HETEROCYCLIC. CHEM.》, vol. 17, 30 November 1980 (1980-11-30), pages 1479 - 1482, XP002353011, DOI: 10.1002/jhet.5570170724 *
J. D. ALBRIGHT等: "Synthesis and Anxiolytic Activity of 6-(Substituted-phenyl)-1, 2, 4-triazolo[4, 3-b]pyridazines", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 24, no. 5, 31 December 1981 (1981-12-31), pages 592 - 600 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026082004A1 (zh) * 2024-10-14 2026-04-23 上海京新生物医药有限公司 稠合杂芳基衍生物及其制备方法与应用

Also Published As

Publication number Publication date
WO2018098499A1 (en) 2018-05-31
US20230322790A1 (en) 2023-10-12
EP3548033A1 (en) 2019-10-09
JP2019535838A (ja) 2019-12-12
CA3045121A1 (en) 2018-05-31
FI3548033T3 (fi) 2024-07-10
PL3548033T3 (pl) 2025-06-02
JP7801794B2 (ja) 2026-01-19
AU2025237912A1 (en) 2025-10-16
US20210188852A1 (en) 2021-06-24
EP4397308A2 (en) 2024-07-10
EP3548033B1 (en) 2024-04-10
EP3548033A4 (en) 2020-09-09
CN110337295B (zh) 2023-06-09
JP2024100974A (ja) 2024-07-26
BR112019010880A2 (pt) 2019-10-01
JP2026062794A (ja) 2026-04-10
US11629146B2 (en) 2023-04-18
DK3548033T3 (da) 2024-07-15
AU2017364901A1 (en) 2019-06-13
JP7495962B2 (ja) 2024-06-05
ES2992063T3 (es) 2024-12-09
AU2023282271A1 (en) 2024-01-18
CA3281817A1 (en) 2026-03-02
CN110337295A (zh) 2019-10-15
CA3045121C (en) 2025-12-16
EP4397308A3 (en) 2024-08-21
PT3548033T (pt) 2024-08-09
JP7105797B2 (ja) 2022-07-25
HUE068842T2 (hu) 2025-01-28
JP2022141773A (ja) 2022-09-29
US20250163068A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
CN110337295B (zh) 化合物以及它们的使用方法
CN116531380B (zh) 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
US11731966B2 (en) Compounds and their methods of use
CN119371426A (zh) 离子通道调节剂
CN118119600A (zh) Sos1抑制剂及其用途
TW202016109A (zh) 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
TW201639829A (zh) 經取代磺醯胺化合物
CN114874209B (zh) 噁二唑瞬时受体电位通道抑制剂
CN114014844B (zh) 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途
HK40014215A (en) Compounds and their methods of use
TW201609691A (zh) 氟甲基取代之吡咯羧醯胺之二
HK40013290A (en) Compounds and their methods of use
HK40013290B (en) Compounds and their methods of use
HK40096088A (zh) 杂环化合物
HK40097687B (zh) 用於治疗癌症的2-杂芳基-3-氧代-2 ,3-二氢哒嗪-4-甲酰胺
HK40097687A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2 ,3-二氢哒嗪-4-甲酰胺
HK40098354A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2，3-二氢哒嗪-4-甲酰胺
HK40035599B (zh) 恶嗪单醯甘油脂肪酶(magl)抑制剂
HK1251815B (zh) 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination